Tubular injury as assessed by histological changes (cell necrosis, loss of brush border, cast formation, tubule dilatation) was evident in all Veh/CIS mice after just two doses of cisplatin, while 30% of BARD/CIS mice did not display tubular injury or elevated urinary KIM-1 even after four doses of cisplatin suggesting that BARD mitigated cisplatin-induced tubular damage in about one-third of mice (Fig. S1A). Here, HAVCR1 is linked to in situ carcinoma.